Skip to Content Facebook Feature Image

Arizona executes a man for killing 4 members of a family in Phoenix in 1993

News

Arizona executes a man for killing 4 members of a family in Phoenix in 1993
News

News

Arizona executes a man for killing 4 members of a family in Phoenix in 1993

2025-10-18 03:54 Last Updated At:04:01

FLORENCE, Arizona (AP) — A man convicted of killing four members of a Phoenix family over 30 years ago in an act of revenge over stolen goods was put to death Friday in Arizona’s second execution of the year.

Richard Kenneth Djerf, 55, died by lethal injection for the killings of Albert Luna Sr. and Patricia Luna; their daughter Rochelle Luna, 18; and son Damien Luna, 5, at their home on Sept. 14, 1993. Djerf, who was in prison for over 29 years, chose not to seek clemency.

His execution was the fourth in the country this week and the 39th of the year.

“Those four innocent victims deserve justice, and their loved ones deserve closure,” said Arizona Attorney General Kris Mayes, whose office sought the execution.

Prosecutors said Djerf blamed another family member, Albert Luna Jr., who did not witness the killings, for an earlier theft of electronics and a gun from his apartment. Djerf became obsessed with exacting revenge and went to the home months later claiming to be delivering flowers, prosecutors said.

Authorities say Djerf sexually assaulted Rochelle Luna and slashed her throat; beat Albert Luna Sr. with an aluminum baseball bat then stabbed and shot him; and tied Patricia and Damien Luna to kitchen chairs before fatally shooting them.

Djerf declined to make any last statement. He did not put up any resistance but took a few heavy breaths and emitted a brief snoring sound after the lethal drugs were administered, John Barcello, deputy director of the Arizona Department of Corrections, Rehabilitation and Reentry, said during a news conference Friday.

No representatives of the victims were present, Barcello said.

It took about 10 minutes for the execution team to insert the IV lines into his veins so the drugs could be administered. After the first of two pentobarbital shots were given, he made several sounds, including a grunt and puffing sound. About 15 minutes elapsed between the first pentobarbital shot and the declaration that he was dead.

Barcello said Djerf’s veins “were not optimal” and it required a few attempts to successfully place the IV.

“By all accounts the process went according to plan and without any incident,” Barcello said. A month ago, Djerf released a statement in which he acknowledged carrying out the killings and apologized for the pain he caused.

Arizona has been criticized in the past for taking too long to insert IVs during lethal injection executions. Experts say it should take seven to 10 minutes from the beginning of insertion until a proclamation of death.

The state has paused executions twice since 2014 amid concerns over its use of the death penalty.

There was a nearly eight-year hiatus brought on by difficulties in obtaining the needed drugs and criticism that a 2014 execution was botched: Joseph Wood was injected with 15 doses of a two-drug combination over two hours, leading him to snort repeatedly and gasp hundreds of times before he died.

Executions resumed in 2022, and three prisoners were put to death that year. They were paused again in 2023 after Democratic Gov. Katie Hobbs ordered a review of the capital punishment protocol and Democratic Attorney General Kris Mayes agreed not to pursue any executions.

The review ended in November 2024, when Hobbs fired a retired federal magistrate she had appointed to examine execution procedures, and the state corrections department announced changes in the lethal injection team.

Arizona last carried out a death sentence in mid-March, executing Aaron Brian Gunches for the 2002 killing of Ted Price.

With Djerf’s execution, there are now 107 prisoners on Arizona’s death row.

Five more executions are scheduled in the U.S. this year — two in Florida and one each in Alabama, Oklahoma and Tennessee, according to the Death Penalty Information Center.

Billeaud reported from Phoenix.

Arizona Attorney General Kris Mayes speaks about the execution of inmate Richard Djerf at the Arizona State Prison, Friday, Oct. 17, 2025 in Florence, Ariz. (AP Photo/Darryl Webb)

Arizona Attorney General Kris Mayes speaks about the execution of inmate Richard Djerf at the Arizona State Prison, Friday, Oct. 17, 2025 in Florence, Ariz. (AP Photo/Darryl Webb)

ADCRR Deputy Director John Barcello speaks about the execution of inmate Richard Djerf at the Arizona State Prison, Friday, Oct. 17, 2025 in Florence, Ariz. (AP Photo/Darryl Webb)

ADCRR Deputy Director John Barcello speaks about the execution of inmate Richard Djerf at the Arizona State Prison, Friday, Oct. 17, 2025 in Florence, Ariz. (AP Photo/Darryl Webb)

FILE = The Arizona State Prison is shown Wednesday, March 19, 2025 in Florence, Ariz. (AP Photo/Darryl Webb,File)

FILE = The Arizona State Prison is shown Wednesday, March 19, 2025 in Florence, Ariz. (AP Photo/Darryl Webb,File)

NEWARK, Del.--(BUSINESS WIRE)--Jan 15, 2026--

QPS Holdings, LLC (QPS), an award-winning contract research organization (CRO) focused on bioanalysis and clinical trials announces the successful implementation of Oracle Argus, a premier pharmacovigilance system designed to support comprehensive safety case management for clinical trials.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260115711485/en/

The adoption of the Oracle Argus drug safety platform underscores QPS’s commitment to advancing patient safety, regulatory compliance, and operational excellence across its clients’ clinical drug development programs. Integrating this industry-standard safety platform strengthens QPS’ ability to capture, manage, and report adverse events in accordance with global regulatory requirements.

“Ensuring patient safety and data integrity is at the heart of what we do when conducting clinical trials,” said Derek Grimes, Executive Vice President of QPS. “Oracle Argus provides us with a robust, scalable solution to support the growing needs of our customer’s clinical trial portfolios and the evolving expectations of regulatory authorities worldwide.”

“Oracle Argus provides QPS Holdings, LLC with a trusted, globally recognized drug safety platform that supports compliance with stringent pharmacovigilance standards and regulations, while streamlining end-to-end safety operations and insights at scale,” said Seema Verma, executive vice president and general manager, Oracle Health and Life Sciences. “With our industry-leading solutions, QPS Holdings, LLC can further transform and elevate its safety case management for customers worldwide.”

The deployment of Oracle Argus will enable QPS to:

As the demand for innovative therapies continues to rise, CROs play a critical role in managing both development speed and patient safety. By leveraging the Oracle Argus platform, QPS is well-positioned to deliver on its mission to accelerate pharmaceutical breakthroughs across the globe by delivering custom-built research services.

###

ABOUT QPS HOLDINGS, LLC

QPS is a global, full-service, GLP/GCP-compliant contract research organization (CRO) delivering the highest grade of discovery, bioanalysis, preclinical and clinical drug development services. Since 1995, QPS has grown from a small bioanalysis shop into a full-service CRO with 1,200+ employees in the US, Europe, Asia and India. Today, QPS offers expanded pharmaceutical contract R&D services with special expertise in pharmacology, DMPK, toxicology, bioanalysis, translational medicine, PBMC processing, central safety labs, clinical trials, and clinical research services. An award-winning leader focused on bioanalysis and clinical trials, QPS is known for proven quality standards, technical expertise, a flexible approach to research, client satisfaction, turnkey laboratories, Phase I/II clinical units, and multi-site clinical research services. For more information, visit http://www.qps.com or email info@qps.com.

ABOUT ORACLE ARGUS

Oracle Argus is an industry-leading, trusted solution for processing, analyzing, and reporting adverse event cases originating in pre-market and post-market drugs, biologics, vaccines, devices, and combination products. Oracle has been a Leader in the IDC MarketScape: Worldwide Life Science R&D Pharmacovigilance Technology Solutions and Consulting Services 2025 Vendor Assessment (doc # US53669225, July 2025). To learn more about Oracle’s pharmacovigilance portfolio visit: https://www.oracle.com/life-sciences/safety-solutions/argus-safety-case-management/. Trademarks: Oracle, Java, MySQL and NetSuite are registered trademarks of Oracle Corporation.

Derek Grimes, EVP, Global Head of Clinical Research at QPS Holdings, LLC.

Derek Grimes, EVP, Global Head of Clinical Research at QPS Holdings, LLC.

Recommended Articles